Group 1 - The "People's Health Star" science popularization initiative was launched in Jianou City, Fujian Province, focusing on improving local residents' health literacy through lectures and diverse health services [1][5] - The initiative addresses the rising incidence of chronic diseases such as cardiovascular diseases and diabetes, which pose significant health threats to the elderly population in China [2] - Experts provided practical health management advice, including regular carotid ultrasound checks and lifestyle habit improvements, to help manage chronic diseases [2] Group 2 - Yiling Pharmaceutical, guided by traditional Chinese medicine theory, aims to innovate drug development in various fields, including cardiovascular health and diabetes, contributing to public health [3] - Yangzu Pharmacy emphasizes quality service and has established a comprehensive pharmaceutical service network to ensure consumers have access to safe and effective medications [3] - The event featured health experts sharing experiences on topics like scientific dietary combinations and mental health adjustments, resonating with the audience [4] Group 3 - A health service area was set up at the event, where experienced general practitioners provided one-on-one health consultations and chronic disease screenings, enhancing community health support [4] - The "People's Health Star" initiative will continue to operate both online and offline, engaging over 30 cities and numerous health experts to improve chronic disease prevention and management at the grassroots level [4]

Group 1 - The core viewpoint of the news is that Yiling Pharmaceutical has been awarded the "2025 ESG Social Responsibility Practice Leading Enterprise" by Guangdong Times Media Group, highlighting its commitment to ESG principles and social responsibility [1][3] - The "Golden Antelope Award" was established to encourage enterprises and individuals leading in ESG practices, showcasing exemplary cases of sustainable development [3] - Yiling Pharmaceutical has developed 17 innovative patented traditional Chinese medicines, with 11 included in the national medical insurance directory and 5 in the national essential drug list, demonstrating its focus on healthcare and innovation [3] Group 2 - Yiling Pharmaceutical integrates ESG principles into its operations by promoting rural revitalization and farmer prosperity through innovative collaboration models, such as "company + base + farmers" [4] - The company has established over 60 standardized medicinal herb bases across 20 provinces in China, ensuring quality and contributing to local economies and ecological sustainability [4] - These bases not only enhance the quality of medicinal herbs but also promote environmental greening and tourism, achieving a balance between economic growth and ecological preservation [4]

Group 1 - The event "Traditional Chinese Medicine (TCM) Nurturing Vitality and Dragon Boat Festival Praying for Health" was held from May 31 to June 2, integrating traditional customs with TCM culture in a vibrant health festival [1][2] - The historical site Yanghe Tower served as a cultural landmark, showcasing the fusion of history and modern health practices, allowing citizens to experience the depth of TCM culture [2][3] Group 2 - The event featured a TCM cultural corridor with two main exhibition areas focusing on "Origin of Meridian Diseases" and "Nurturing Vitality," presenting the TCM meridian theory and the essence of health from Confucianism, Buddhism, Taoism, and medicine [3][4] - Cultural performances included the "Chinese Meridian Exercise," which combined TCM theory with traditional health practices, promoting physical well-being through movement [4][6] Group 3 - Interactive experiences were provided, including free TCM consultations where experts offered personalized health advice based on individual conditions, along with free tastings of herbal beverages [6][7] - The event also featured a DIY section for making herbal sachets, allowing families to engage with TCM traditions and understand the practical applications of ancient wisdom [8][10] Group 4 - A series of lectures on the "Eight Principles of Meridian Health" were conducted, emphasizing the importance of meridian health, energy nurturing, appropriate exercise, and mental well-being [10] - The initiative aimed to modernize TCM and make it appealing to younger generations, promoting a cultural revival and health awareness among the public [10]

Core Viewpoint - The event "Traditional Chinese Medicine (TCM) Health and Wellness Market" held in Zhengding Ancient City showcases the integration of TCM culture with modern health practices, promoting public awareness and understanding of TCM's benefits for health management [1][12]. Group 1: Event Overview - The event took place from May 31 to June 2, featuring a large-scale market focused on TCM culture, organized by Yiling Pharmaceutical in collaboration with local authorities [1]. - The venue, Yanghe Tower, served as a historical bridge connecting ancient and modern practices, emphasizing the enduring appeal of TCM in health preservation [1]. Group 2: Interactive Experience Zones - Three interactive zones were established to enhance public engagement with TCM, including health markets, performance showcases, and hands-on TCM project experiences [2]. - The East Square featured demonstrations of "Chinese Meridian Exercises" and expert lectures on common health misconceptions, attracting many participants [3]. - The West Square offered free health consultations and screenings by TCM practitioners, alongside healthy culinary offerings from Yiling's hotel, promoting a holistic approach to health [4]. Group 3: Educational Initiatives - The second floor of Yanghe Tower hosted health-themed lectures that integrated the essence of Confucianism, Buddhism, Daoism, and TCM, focusing on the "Eight Principles of Meridian Health" [5]. - The cultural corridor presented a systematic overview of TCM's historical development and its relevance in modern health practices, including innovative research in anti-aging by Yiling Pharmaceutical [7]. Group 4: TCM Preventive Health Philosophy - The TCM philosophy of "Preventing Disease Before It Occurs" emphasizes early intervention and health management, rooted in ancient texts like the "Huangdi Neijing" [8]. - Yiling Pharmaceutical aligns its product development with this philosophy, offering a range of health management products aimed at various health demographics [8]. Group 5: Cultural Revival and Public Engagement - The event reflects a growing trend among younger generations to embrace TCM principles, supported by national policies promoting TCM's innovation and cultural transmission [12]. - Attendees expressed a desire for more such events to deepen their understanding and appreciation of TCM culture, highlighting the importance of public engagement in health education [12].

私域选品新趋势：从"卖货"到"卖解决方案" 传统私域运营依赖"低价爆款"的单一逻辑，陷入同质化竞争与用户流失困境。如今消费者对健康产品的 需求从"概念营销"转向"实效改善"，私域选品正从单纯'卖货'向'卖解决方案'转型升级—— 兼具功效确 定性、服务延续性、社交传播性的产品，成为破局关键。 "高复购的健康产品必须解决两个核心问题：一是真实可感知的功效，二是持续的服务价值。"沸点会现 场，以岭健康相关负责人指出，"以岭的产品不是简单的中药材叠加，而是以'通络养生八字经'(通络、 养精、动形、静神)为理论指导，结合现代健康需求，形成的中医专利组方产品，针对现代人亚健康痛 点，提供从理论到产品的全链条体系化健康解决方案。" 当"边熬边补"的朋克养生升级为"精准调理"的科学管理，养生消费迈入全新发展阶段。数据显示，当前 我国年轻人群体中，养生青年占比已经高达83.7％，保健养生消费在18 - 35岁年轻人群的消费榜单中强 势崛起，稳稳跻身前三甲。这一代年轻消费者，秉持着"功能性养生零食+即时调理"的全新消费诉求， 正有力推动中医药大健康产品成为消费市场的"新宠儿"。 在此背景下，以岭健康以"通络养生八字经"为核心，打 ...

证券代码：002603 证券简称：以岭药业 公告编号：2025-022 石家庄以岭药业股份有限公司 2024 年年度股东大会决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记载、 误导性陈述或重大遗漏。 特别提示： 1、本次股东大会未出现否决议案的情形； 2、本次股东大会没有涉及变更前次股东大会决议。 一、会议召开和出席情况 3、会议召开方式：现场投票、网络投票相结合 4、会议召集人和主持人：公司董事会。董事长吴相君先生主持会议。 本次会议的召集、召开程序及表决方式符合有关法律、行政法规、部门规章、 规范性文件和公司章程的规定。 （二）会议出席情况 1、出席会议的总体情况 出席本次股东大会现场会议和参加网络投票的股东及股东代理人共 1,145 人， 代表股份 942,896,393 股，占公司总股本的 56.4370%。 （一）会议召开情况： 1、会议召开时间： （1）现场会议时间：2025 年 5 月 26 日下午 14:30 （2）网络投票时间：2025 年 5 月 26 日。其中，通过深圳证券交易所交易 系统进行网络投票的时间为 2025 年 5 月 26 日上午 9:15— ...

北京市东城区建国门内大街 26 号新闻大厦 7 层、8 层 电话：010-88004488/66090088 传真：010-66090016 邮编：100005 北京国枫律师事务所 关于石家庄以岭药业股份有限公司 2024 年年度股东大会的 法律意见书 国枫律股字[2025]A0286 号 致：石家庄以岭药业股份有限公司（贵公司） 北京国枫律师事务所（以下简称"本所"）接受贵公司的委托，指派律师出席并 见证贵公司 2024 年年度股东大会（以下简称"本次会议"）。 本所律师根据《中华人民共和国公司法》（以下简称"《公司法》"）、《中华 人民共和国证券法》（以下简称"《证券法》"）、《上市公司股东会规则》、《律 师事务所从事证券法律业务管理办法》（以下简称"《证券法律业务管理办法》"）、 《律师事务所证券法律业务执业规则（试行）》（以下简称"《证券法律业务执业规 则》"）等相关法律、行政法规、规章、规范性文件及《石家庄以岭药业股份有限公 司章程》（以下简称"《公司章程》"）的规定，就本次会议的召集与召开程序、召 集人资格、出席会议人员资格、会议表决程序及表决结果等事宜，出具本法律意见书。 对本法律意见书的出具， ...

Core Viewpoint - The implementation of the "Private Economy Promotion Law" is a significant milestone for the legal framework supporting the private economy in China, emphasizing the importance of technological innovation and providing legal protections for private enterprises [1]. Group 1: Private Economy Promotion Law - The "Private Economy Promotion Law" officially took effect on May 20, marking the first foundational law specifically addressing the development of the private economy in China [1]. - The law highlights the government's commitment to supporting the private economy, particularly in the realm of technological innovation, which is crucial for high-quality development [1]. - The law establishes a legal framework that protects the rights and interests of private economic organizations and their operators, ensuring equal access to resources and support from the state [1]. Group 2: Technological Innovation - The private economy is recognized as a vital force in technological innovation, accounting for over 90% of national high-tech enterprises and contributing more than 70% of technological innovation outcomes [1]. - The law dedicates a specific chapter to technological innovation, encouraging private economic organizations to actively participate in national technology projects and to lead major technological breakthroughs [1]. - It emphasizes the protection of original innovations and the application of new technologies within private enterprises, signaling a legal commitment to fostering innovation [1]. Group 3: Company Development - Yiling Pharmaceutical, established for over 30 years, has focused on technological innovation and the transformation of research outcomes, successfully undertaking several national research projects and earning multiple national awards for significant scientific achievements [2]. - The company plans to leverage the new law to enhance its focus on technological innovation and research, aiming to develop more traditional Chinese medicines tailored to the genetic and health characteristics of the Chinese population [2].

Core Viewpoint - The article highlights the development of the honeysuckle industry in Julu County, Xingtai City, as a key agricultural sector that supports local farmers' income and promotes rural revitalization through collaboration with Yiling Pharmaceutical [1][10]. Industry Overview - Julu County is recognized as one of the three major production areas for honeysuckle in China, with a cultivation area of 130,000 acres and an annual production of 14,000 tons of dried flowers, accounting for over 60% of the national total [6]. - The local climate and soil conditions are ideal for honeysuckle cultivation, with the main variety "Juhua No. 1" yielding up to 200 kg of dried flowers per acre [8]. Company Initiatives - Yiling Pharmaceutical has established a "company + base + farmer" model in collaboration with local government and agricultural cooperatives, creating standardized honeysuckle planting bases covering 3,100 acres [10]. - The company provides technical guidance and management training to farmers, ensuring quality and yield, with guaranteed purchase agreements [12]. Economic Impact - The standardized planting bases have created over 2,000 jobs during the harvesting season, with daily wages of 100 yuan per worker, and potential earnings of around 20,000 yuan per acre [13]. - Farmers report high yields, with some achieving over 1,000 pounds of wet flowers per acre, translating to significant income during favorable market conditions [12]. Quality Control and Sustainability - Yiling Pharmaceutical implements comprehensive management from seed sourcing to processing, ensuring traceability and quality control throughout the supply chain [14]. - The company promotes standardized planting and green pest control, aligning with ecological protection and rural revitalization goals [14].

Group 1 - The company, Jihong Co., Ltd. (02603), plans to conduct an initial public offering (IPO) from May 19 to May 22, 2025, offering a total of 67.91 million shares, with 10% allocated for public sale in Hong Kong and 90% for international sale [1] - The proposed price range for the shares is between HKD 7.48 and HKD 10.68, with the expected listing date for H-shares on May 27, 2025 [1] - The company operates in cross-border social e-commerce and paper packaging for fast-moving consumer goods (FMCG), providing a one-stop service for FMCG clients since its establishment in 2003 [1] Group 2 - Following its listing on the Shenzhen Stock Exchange in 2016, the company has successfully transformed and expanded its business, achieving notable results in both operational and financial aspects [2] - According to Zhi Shi Consulting, the company ranks second among B2C export e-commerce companies in China with a market share of 1.3% in 2024, focusing on the Asian market [2] - The company is also the leading paper packaging company for FMCG in mainland China, holding a market share of 1.2% in 2024 [2] Group 3 - At an offering price of HKD 9.08 per share, the company expects to net approximately HKD 505.4 million from the global offering, with around 40% allocated for overseas market expansion [2] - Approximately 35% of the funds will be used for technology development, including enhancing research and development capabilities, data analysis, and expanding revenue sources through Jimiaoyun [2] - About 15% will be allocated to expanding the brand portfolio and developing existing proprietary brands, while 10% will be used for working capital and general corporate purposes [2] Group 4 - The company has entered into cornerstone investment agreements, with cornerstone investors agreeing to purchase shares worth USD 20 million at the offering price, including Timber Kangaroo Capital Limited and Yulong International Capital Limited [3] - Notable investors include Ms. Shen Zhenyu, the chairwoman of Harbin Yuheng Pharmaceutical Co., Ltd. (002437.SZ) [3]